<

ABSCIENCES (EPA:AB) AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy

Transparency directive : regulatory news

08/01/2020 19:14



Other stories

28/03/2024 18:00
28/03/2024 17:12
28/03/2024 16:02
28/03/2024 17:41
28/03/2024 19:15
28/03/2024 13:03
28/03/2024 19:27
28/03/2024 18:25
28/03/2024 12:36
28/03/2024 11:51
28/03/2024 16:43
28/03/2024 17:33
28/03/2024 09:33
28/03/2024 07:06
28/03/2024 16:56
28/03/2024 18:26
28/03/2024 17:38
28/03/2024 09:59
28/03/2024 13:33
28/03/2024 10:49
28/03/2024 14:28
27/03/2024 15:52
28/03/2024 19:00
28/03/2024 18:16
28/03/2024 11:03
28/03/2024 09:01
28/03/2024 18:29
28/03/2024 13:59
28/03/2024 10:44
28/03/2024 17:53
27/03/2024 21:46
27/03/2024 23:22
27/03/2024 13:40
28/03/2024 17:23
28/03/2024 11:40
28/03/2024 13:25
28/03/2024 02:42
28/03/2024 06:00